MBrace Therapeutics
PrivateLast Round
Series B
Nov 14, 2023
Total Funding Raised
$135M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
MBrace Therapeutics is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat cancer using its proprietary SPARTA technology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MBrace Therapeutics Comparables
Compare MBrace Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adcentrx Therapeutics | 91% | |
| Aarvik Therapeutics | 89% | |
| Mythic Therapeutics | 89% |
MBrace Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 14, 2023 | ||||
| Series A | Nov 1, 2021 | ||||
| Series A | Oct 1, 2021 | ||||
| Seed | Jun 1, 2020 |
Key People
Founding team and executive leadership
MBrace Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TD Securities | Series B |
| Blue Owl Capital | Series B |
| Avidity Partners | Series B |
| Venrock | Series A, Series B |
| TPG | Series B |
| Alta Partners | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 35% MoM.
- May 17, 2026
Monthly visitors increased 68% MoM.
MBrace Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MBrace Therapeutics's valuation, stock price, and market status.
Is MBrace Therapeutics a public or private company?
MBrace Therapeutics is a private company.
What is the current stock price of MBrace Therapeutics?
MBrace Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is MBrace Therapeutics worth (valuation)?
Valuation information for MBrace Therapeutics is not publicly available.
Can I buy MBrace Therapeutics stock?
MBrace Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MBrace Therapeutics's last funding round?
MBrace Therapeutics's most recent funding round was Series B on November 14, 2023.
Who are the main investors in MBrace Therapeutics?
Key investors in MBrace Therapeutics include TPG.
Will MBrace Therapeutics IPO soon?
No public IPO plans have been announced for MBrace Therapeutics.
How can I track MBrace Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MBrace Therapeutics's secondary market activity and sign up for updates.